KALV Stock Analysis: Buy, Sell, or Hold?
KALV - KalVista Pharmaceuticals, Inc. Common Stock
$27.00
0.01 (0.04%)
â˛
5d:
+0.19%
30d:
+1.09%
90d:
+48.03%
WAIT
LOW Confidence
Analysis Updated: Jun 10, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When KALV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: KALV is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: KALV is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: KALV is currently trading at $27.00, which is considered fair based on recent price action.
Technical Outlook: Technically, KALV is in a strong uptrend. The price is currently testing key support at $26.77. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KALV is in a strong uptrend. The price is currently testing key support at $26.77. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
49/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
64.2%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- NEUTRAL: Near Wall St target ($28.60)
- WARNING: Composite score 49/100 in the bottom quintile â this cohort historically lags the market
Support & Resistance Levels
Support Level
$26.77
Resistance Level
$27.00
Current Trend
Strong Uptrend
Technical data as of
Jun 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.68
Wall Street Target
$28.60
(+5.9%)
Revenue Growth (YoY)
30.7%
Profit Margin
-118.7%
Share & Embed Analysis
Last updated: September 02, 2026 8:05 PM ET
Data refreshes hourly during market hours. Next update: 9:05 PM
Data refreshes hourly during market hours. Next update: 9:05 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KALV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Brian Piekos
SELL
1862 shares
2026-04-17
Nicole Sweeny
SELL
1862 shares
2026-04-17
Paul K Audhya
SELL
2686 shares
2026-04-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$55 | 59 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$92 | 42 HOLD |
|
GPCR
Structure Therapeutics IâĻ |
STRONG BUY
14 analysts |
$105 | 56 HOLD |
